MCID: OVR012
MIFTS: 47

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 51 14 69
Cystadenoma, Serous 69
Serous Cystadenoma 12
Cystadenoma Serous 51

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 46 C7978

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to pancreatic serous cystadenoma and endometriosis of ovary. An important gene associated with Ovarian Serous Cystadenocarcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Pathways in cancer and TRAF Pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 pancreatic serous cystadenoma 34.1 PGR VEGFA
2 endometriosis of ovary 29.9 ESR2 PGR
3 cystadenocarcinoma 29.8 AKT1 ESR2 PGR VEGFA ZNF217
4 endometriosis 29.5 ESR2 PGR VEGFA
5 ovarian cancer 28.0 AKT1 BCL2 ESR2 FSHR PGR VEGFA
6 serous cystadenocarcinoma 27.9 AKT1 BCL2 ESR2 PGR UBE4A USP14
7 cystadenoma 10.9
8 pancreatitis 10.7
9 benign metastasizing leiomyoma 10.3 BCL2 PGR
10 cervical carcinosarcoma 10.3 BCL2 PGR
11 adenoma 10.2
12 progesterone resistance 10.1 ESR2 PGR
13 adenomyosis 10.1 PGR VEGFA
14 progesterone-receptor positive breast cancer 10.1 ESR2 PGR
15 gender identity disorder 10.1 ESR2 PGR
16 epithelioid hemangioendothelioma 10.1 VEGFA YAP1
17 gastric lymphoma 10.1 BCL2 VEGFA
18 uterine body mixed cancer 10.1 ESR2 PGR
19 microcystic adenoma 10.0
20 obstructive jaundice 10.0
21 adenocarcinoma 10.0
22 adenoma of the pancreas 10.0
23 soft tissue sarcoma 10.0 BCL2 VEGFA
24 primary effusion lymphoma 10.0 AKT1 VEGFA
25 von hippel-lindau syndrome 9.9
26 mycobacterium tuberculosis 1 9.9
27 hydrops, lactic acidosis, and sideroblastic anemia 9.9
28 portal hypertension 9.9
29 endosalpingiosis 9.9
30 neuroendocrine tumor 9.9
31 struma ovarii 9.9
32 leydig cell tumor 9.9
33 sertoli-leydig cell tumor 9.9
34 cystadenofibroma 9.9
35 cataract 32, multiple types 9.9
36 leukemia 9.9
37 plasma cell leukemia 9.9
38 chronic enteropathy associated with slco2a1 gene 9.9
39 ovary adenocarcinoma 9.8 HRAS ZNF217
40 hepatitis 9.8
41 estrogen excess 9.8 ESR2 FSHR PGR
42 endometrial adenocarcinoma 9.8 ESR2 PGR VEGFA
43 reproductive system disease 9.8 ESR2 FSHR PGR
44 angiomatous meningioma 9.7 PGR VEGFA
45 male reproductive organ cancer 9.7 AKT1 ESR2 VEGFA
46 ovary serous adenocarcinoma 9.7 HRAS UBE4A USP2 ZNF217
47 infertility 9.7 ESR2 FSHR PGR
48 ovarian cystadenocarcinoma 9.7 HRAS UBE4A USP2 ZNF217
49 mixed cell type cancer 9.6 HRAS PGR
50 differentiated thyroid carcinoma 9.6 BCL2 HRAS VEGFA

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.62 USP2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.62 USP14
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.62 BCL2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.62 BCL2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.62 USP2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.62 BCL2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 BCL2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.62 USP2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.62 USP2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.62 HRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.62 BCL2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.62 BCL2 HRAS USP14 USP2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 BCL2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.62 BCL2 HRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.62 HRAS USP14
16 Decreased ionizing radiation sensitivity GR00232-A-1 9.43 AKT1 ESR2 PGR UBE4A USP2 YAP1

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 BCL2 ESR2 FSHR HRAS PGR USP14
2 cardiovascular system MP:0005385 10.16 AKT1 BCL2 ESR2 FSHR HRAS PGR
3 homeostasis/metabolism MP:0005376 10.16 AKT1 BCL2 ESR2 FSHR HRAS PGR
4 cellular MP:0005384 10.15 AKT1 BCL2 ESR2 FSHR PGR USP14
5 endocrine/exocrine gland MP:0005379 10.13 AKT1 BCL2 ESR2 FSHR HRAS PGR
6 integument MP:0010771 10.09 AKT1 BCL2 ESR2 FSHR HRAS PGR
7 mortality/aging MP:0010768 10.06 AKT1 BCL2 ESR2 FSHR HRAS PGR
8 neoplasm MP:0002006 9.92 AKT1 BCL2 ESR2 FSHR HRAS PGR
9 muscle MP:0005369 9.91 PGR USP14 VEGFA YAP1 AKT1 BCL2
10 nervous system MP:0003631 9.86 AKT1 BCL2 ESR2 FSHR HRAS USP14
11 renal/urinary system MP:0005367 9.63 YAP1 BCL2 ESR2 HRAS USP2 VEGFA
12 reproductive system MP:0005389 9.56 AKT1 BCL2 ESR2 FSHR PGR USP14
13 skeleton MP:0005390 9.17 AKT1 ESR2 FSHR HRAS PGR USP14

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
8 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Mitogens Phase 3,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Antibodies, Monoclonal Phase 3,Phase 1
17 Endothelial Growth Factors Phase 3,Phase 1
18 Immunoglobulins Phase 3,Phase 1
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 1
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Analgesics Phase 3,Phase 1
23 Micronutrients Phase 3
24 Trace Elements Phase 3
25 Vitamin B Complex Phase 3
26 Vitamins Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 1
28 Folate Nutraceutical Phase 3
29 Vitamin B9 Nutraceutical Phase 3
30
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
31
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
32
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
33
Belinostat Approved, Investigational Phase 2 866323-14-0
34
Gemcitabine Approved Phase 2 95058-81-4 60750
35
Metformin Approved Phase 2,Phase 1 657-24-9 4091 14219
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
38
Everolimus Approved Phase 2 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
40
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
41
Docetaxel Approved May 1996, Investigational Phase 1, Phase 2 114977-28-5 148124 9877265
42
Doxil Approved June 1999 Phase 2,Phase 1 31703
43
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
44 topoisomerase I inhibitors Phase 2,Phase 1
45 Adjuvants, Immunologic Phase 2,Phase 1
46 Histone Deacetylase Inhibitors Phase 2
47 Anti-Bacterial Agents Phase 2,Phase 1
48 Protein Kinase Inhibitors Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 2,Phase 1
50 Hypoglycemic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 61)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
7 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
8 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
9 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
10 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
11 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
12 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
13 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
14 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
15 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
16 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
17 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
18 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
19 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
20 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 paclitaxel;carboplatin;docetaxel;metformin hydrochloride;placebo
21 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
22 Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 selumetinib
23 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
24 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
25 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
26 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
27 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
28 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
29 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
30 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
31 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
32 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
33 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
34 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
35 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
36 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
37 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
38 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
39 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
40 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
41 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
42 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
43 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
44 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
45 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
46 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1 Sapanisertib
47 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
48 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT01074411 Phase 1 Bortezomib;Carboplatin
49 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Active, not recruiting NCT00357448 Phase 1
50 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

38
Ovary, Endothelial, Bone Marrow, Liver, Bone, Brain, Breast

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 19)
# Title Authors Year
1
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
2
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
3
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
4
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
5
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
6
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
7
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
8
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
9
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
10
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
11
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
12
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
13
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
14
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
15
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000
16
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. ( 9506768 )
1998
17
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. ( 2314830 )
1990
18
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). ( 3165255 )
1988
19
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. ( 3598277 )
1987

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show all 48)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
5 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
17 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
21 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
22 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
23 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
24 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
25 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
26 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
27 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
28 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
29 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
30 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
31 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
32 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
33 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
34 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
35 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
36 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
37 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
38 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
39 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
40 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
41 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
42 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
44 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
45 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519981 GRCh37 Chromosome 17, 7577569: 7577569
46 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
47 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
48 TP53 NM_000546.5(TP53): c.817C> A (p.Arg273Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913343 GRCh37 Chromosome 17, 7577121: 7577121

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1 12.52 AKT1 BCL2 ESR2 HRAS VEGFA
2
Show member pathways
12.45 AKT1 BCL2 HRAS VEGFA
3
Show member pathways
12.43 AKT1 BCL2 ESR2 HRAS PGR
4
Show member pathways
12.36 AKT1 BCL2 HRAS YAP1
5
Show member pathways
12.33 AKT1 BCL2 HRAS VEGFA
6
Show member pathways
12.23 AKT1 BCL2 HRAS
7
Show member pathways
12.19 AKT1 BCL2 ESR2 HRAS
8
Show member pathways
12.1 AKT1 HRAS VEGFA
9
Show member pathways
12.06 AKT1 BCL2 HRAS
10
Show member pathways
12.03 AKT1 BCL2 HRAS
11 12 AKT1 BCL2 VEGFA
12
Show member pathways
11.99 AKT1 HRAS VEGFA
13 11.93 AKT1 BCL2 VEGFA
14
Show member pathways
11.91 AKT1 BCL2 HRAS
15 11.89 AKT1 BCL2 USP2
16 11.87 AKT1 BCL2 HRAS
17
Show member pathways
11.87 AKT1 BCL2 ESR2 HRAS VEGFA
18
Show member pathways
11.84 AKT1 BCL2 HRAS
19 11.82 AKT1 BCL2 HRAS
20 11.79 AKT1 BCL2 HRAS
21 11.78 AKT1 BCL2 VEGFA
22
Show member pathways
11.75 HRAS PGR YAP1
23 11.67 AKT1 BCL2 VEGFA
24
Show member pathways
11.64 AKT1 BCL2 HRAS
25
Show member pathways
11.6 AKT1 HRAS VEGFA
26
Show member pathways
11.16 HRAS VEGFA
27 11.16 AKT1 HRAS
28 11.16 AKT1 HRAS
29 11.14 AKT1 BCL2 HRAS
30 11.13 BCL2 ESR2
31 11.12 AKT1 HRAS
32 11.1 AKT1 FSHR
33 11.08 AKT1 ESR2
34 11.03 AKT1 VEGFA
35 11.01 AKT1 BCL2
36 11 AKT1 BCL2
37 11 ESR2 HRAS
39 10.94 AKT1 BCL2 YAP1
40 10.92 AKT1 BCL2 HRAS VEGFA
41 10.85 AKT1 HRAS
42 10.84 ESR2 FSHR PGR

GO Terms for Ovarian Serous Cystadenocarcinoma

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.32 AKT1 BCL2 ESR2 HRAS PGR UBE4A

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.76 AKT1 BCL2 HRAS YAP1
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.7 ESR2 PGR YAP1
3 positive regulation of protein phosphorylation GO:0001934 9.67 AKT1 HRAS VEGFA
4 cellular response to hypoxia GO:0071456 9.61 AKT1 BCL2 VEGFA
5 cell aging GO:0007569 9.55 BCL2 HRAS
6 cellular response to gamma radiation GO:0071480 9.54 HRAS YAP1
7 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.51 AKT1 VEGFA
8 apoptotic mitochondrial changes GO:0008637 9.48 AKT1 BCL2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.43 AKT1 BCL2 VEGFA
10 growth GO:0040007 9.4 BCL2 VEGFA
11 positive regulation of organ growth GO:0046622 9.37 AKT1 YAP1
12 positive regulation of cell proliferation GO:0008284 9.35 AKT1 BCL2 HRAS VEGFA YAP1
13 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.32 FSHR YAP1
14 progesterone receptor signaling pathway GO:0050847 9.16 PGR YAP1
15 negative regulation of gene expression GO:0010629 8.92 AKT1 HRAS PGR VEGFA

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.73 AKT1 BCL2 ESR2 FSHR HRAS PGR
2 protein phosphatase 2A binding GO:0051721 9.26 AKT1 BCL2
3 steroid binding GO:0005496 9.16 ESR2 PGR
4 identical protein binding GO:0042802 9.1 AKT1 BCL2 ESR2 PGR USP2 VEGFA

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....